Annual Securities Report

Overview

The report covers TMS's irregular 10-month fiscal period ending December 31, 2025. It highlights the entry of lead candidate TMS-007 into the global ORION Phase 2/3 trial and the successful completion of TMS-008's Phase 1 clinical trial. The company manages sustainability-related risks and opportunities together with other management risks and opportunities. It has not set quantitative indicators or targets for human-resource and internal-environment development policies.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 March 2025 – 31 December 2025
Publication date: 30 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services